NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies, reported positive clinical data from a Phase 1 trial of INB-100, an allogeneic ...

IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...

Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial ...

IN8bio’s are centered on populating the expansion cohort for the INB-100 trial. The scientific team has met with the FDA in a Type B meeting to help guide the design of the registrational path for INB ...

Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025.

IN8bio (NASDAQ:INAB) stock rose ~110% on Monday after the company reported data from a phase 1 trial of INB-100 in patients with leukemia. The company said that data showed that 100% of evaluable ...

Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial ...

Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond one year Company to host conference call at 8:30am EST today. Use this ...

INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...

A phase II study of an anti-telomerase CD4+ T-helper vaccine (UCPVax) with or without temozolomide in newly diagnosed glioblastoma.

Indústrias Nucleares do Brasil has signed a contract with Amazônia Azul Technologias de Defesa SA (Amazul) to provide engineering services for the second phase of the uranium enrichment plant at INB's ...

The National Nuclear Energy Commission has given authorisation for Indústrias Nucleares do Brasil to seek an international buyer for 5.7 tonnes of U3O8 enriched to 3.2% uranium-235. INB's Resende ...